Develops immuno-oncology and targeted therapies for the treatment of solid tumors and hematologic cancers.
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in immunotherapy and targeted oncology treatments aimed at patients with solid tumor cancers. The company focuses on acquiring, developing, and commercializing novel therapies to address critical unmet needs in cancer care. At the forefront of its pipeline is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that targets programmed death ligand-1 (PD-L1), disrupting its interaction with programmed death receptor-1 and B7.1 receptors. Additionally, Checkpoint Therapeutics is advancing CK-302, a human agonistic antibody designed to activate signaling in GITR expressing cells.
Beyond immunotherapy, Checkpoint Therapeutics is developing Olafertinib, a third-generation inhibitor of the epidermal growth factor receptor (EGFR), tailored for non-small cell lung cancer patients with EGFR mutations. The company's diverse portfolio also includes CK-103, a potent inhibitor targeting bromodomain and extra-terminal bromodomains, and an anti-carbonic anhydrase IX (CAIX) antibody designed to recognize and eliminate CAIX expressing cells through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Collaborative efforts with TG Therapeutics, Inc. further bolster Checkpoint Therapeutics' capabilities in developing and commercializing treatments, particularly in the realm of hematological malignancies.
Established in 2014 and headquartered in Waltham, Massachusetts, Checkpoint Therapeutics operates as a subsidiary of Fortress Biotech, Inc. The company's strategic focus on innovative therapies underscores its commitment to advancing cancer treatment paradigms and improving outcomes for patients worldwide, reinforcing its position as a leader in the evolving landscape of oncology therapeutics.